Magenta Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$305.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Magenta Therapeutics's estimated annual revenue is currently $8.5M per year.(i)
  • Magenta Therapeutics received $52.0M in venture funding in April 2018.
  • Magenta Therapeutics's estimated revenue per employee is $76,116
  • Magenta Therapeutics's total funding is $305.9M.

Employee Data

  • Magenta Therapeutics has 112 Employees.(i)
  • Magenta Therapeutics grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on key areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.

keywords:N/A

$305.9M

Total Funding

112

Number of Employees

$8.5M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Magenta Therapeutics News

2022-04-06 - Magenta Therapeutics Focuses R&D and Operational ...

--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the...

2022-04-06 - Stem cell startup Magenta Therapeutics cuts staff by 14 ...

Magenta Therapeutics Inc. has cut its workforce by 14%, or about 11 people, as it scales back work on a drug for blood cancers and...

2022-04-06 - Magenta Therapeutics Cuts Workforce by 14%, Shifts Focus to ...

Changes in Magenta's operating procedures stem from its recent success in a Phase I/II targeted conditioning clinical trial of therapeutic MGTA-...

2021-05-14 - MAGENTA THERAPEUTICS, INC. Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Investors (Form 8-K)

Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass.-(BUSINESS WIRE)- May 12, 2021-Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell trans ...

2021-05-12 - MAGENTA THERAPEUTICS, INC. Magenta Therapeutics : Announces $86.4 Million Common Stock Investment from Multiple Investors

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional inve ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.5M11211%N/A
#2
N/A1125500%N/A
#3
$32.5M112N/AN/A
#4
$17.4M11226%$173M
#5
$17.5M11333%$184M

Magenta Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-11-17$48.5MAThird Rock Ventures, LLCArticle
2017-05-03$50.0MBGoogle VenturesArticle
2018-04-10$52.0MCCasdin CapitalArticle